Moteur de recherche d’entreprises européennes
Financement de l’UE (5 999 986 €) : Management of chronic cardiometabolic disease and treatment discontinuity in adult ADHD patients Hor28/01/2021 Programme de recherche et d'innovation de l'UE « Horizon »
Vue d’ensemble
Texte
Management of chronic cardiometabolic disease and treatment discontinuity in adult ADHD patients
TIMESPAN's main objective is to advance the management of patients with Attention Deficit Hyperactivity Disorders (ADHD) and co-occurring cardiometabolic disease by improving available treatments and risk stratification. Emerging evidence points at substantial comorbidity and shared genetics between adult ADHD and cardiometabolic diseases (i.e., Obesity, Type-2 Diabetes and cardiovascular disease). Inadequate treatment of cardiometabolic disease is strongly associated with premature death and substantial societal costs. National guidelines of cardiometabolic disease have stressed the importance of co-occurring psychiatric disorders. However, even though ADHD is a common (prevalence ≈2 to 5% in adults) and serious complex chronic condition, knowledge about appropriate management of adults with ADHD and co-occurring cardiometabolic disease is lacking. We will address the main objective using existing large-scale cohort studies and linked electronic health record databases in multiple countries with different health care systems. We also use smartphones and wearable devices to obtain novel real-time and multi-parametric measurements of ADHD medication treatment and cardiometabolic risks. The combined use of unparalleled data sources and new technologies for data collection, management, analytics will identify optimized and personalized multidisciplinary treatment approaches that minimise harm and maximise positive changes in disease prognosis and improve treatment discontinuity. TIMESPAN is expected to improve the clinical outcomes, as well as quality of life in adult ADHD patients with co-occurring cardiometabolic disease and also to also facilitates developments of new technological tools for advanced data management, monitoring and analytics for European stakeholders. TIMESPAN strategies to inform clinicians, patients, health authorities, and general public allow for a sustainable implementation of our findings (e.g. recommendations for treatment guidelines).
| Aarhus Universitet | 600 000 € |
| ACADEMISCH ZIEKENHUIS GRONINGEN | 400 000 € |
| ADD Information Services | 30 000 € |
| CONCENTRIS RESEARCH MANAGEMENT GmbH | 558 250 € |
| Empatica Srl | 300 000 € |
| Fundacio Hospital Universitari Vall D'Hebron - Institut de Recerca | 499 986 € |
| Haskoli Islands | 100 000 € |
| Karolinska Institutet | 400 000 € |
| King's College London | 1 520 000 € |
| Orebro University | 366 750 € |
| TARTU ULIKOOL | 200 000 € |
| The European Association for the Study of Obesity - Ireland CLG | 25 000 € |
| THE RESEARCH Foundation OF STATE UNIVERSITY OF NEW YORK | 400 000 € |
| THE University OF Hong Kong | 0,00 € |
| Universitetet I Bergen | 400 000 € |
| University College London | 200 000 € |
| University OF NEW South Wales | 0,00 € |
https://cordis.europa.eu/project/id/965381
Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel.
Les visualisations de "Aarhus Universitet - Financement de l’UE (5 999 986 €) : Management of chronic cardiometabolic disease and treatment discontinuity in adult ADHD patients"
sont mis à disposition par
North Data
et peuvent être réutilisées selon les termes de la licence
Creative Commons CC-BY.
